Based on published clinical guidance · Last updated 29 October 2026
Yes; the early stages often have no symptoms, so apparently clear vision does not rule out retinal damage. NEI explains that changes can develop before you notice reading or distance problems. Attend screening invitations and ordinary eye examinations, and report a new visual change between visits rather than waiting until the eye becomes painful. [11]
Yes; both type 1 and type 2 diabetes can cause diabetic retinopathy. HSE includes both in Diabetic RetinaScreen. The risk and timing of changes vary with your history and medical factors, so your eye-care plan should reflect your findings rather than the diabetes label alone. Bring details of previous screening and any retinal treatment. [1][3]
It is swelling in the macula, the central retina used for detailed vision. Cochrane explains that leakage associated with diabetes can thicken this area and reduce sight. It is related to retinopathy but is not the same as every retinal change. OCT and examination help establish whether swelling explains your symptoms and what treatment is appropriate. [5][4]
Yes; diabetic retinopathy can cause serious permanent sight loss if it is not detected and managed. HSE explains that early detection and treatment can reduce damage. Blindness is not inevitable, and an individual outlook depends on the retinal findings. Keep appointments even when vision feels normal and seek assessment promptly for a new change. [1][11]
The HSE programme is for people in Ireland with diabetes aged 12 years and older. Registration and consent are required, and the screening programme is free. Ask your GP or diabetes team to help if you are not registered. Eligibility for screening does not replace a specialist referral when symptoms or existing retinal disease need assessment. [1]
Most people are screened annually; HSE allows a two-year interval after the last two screenings show no retinopathy. Some people need closer surveillance or treatment. Follow the invitation and result letter for your pathway. This is a screening schedule, not the review interval for active macular oedema, proliferative disease or a course of eye injections. [1][2]
No; HSE states that diabetic retinal screening may not detect other eye conditions. Continue ordinary eye examinations for your broader eye health and glasses needs. A reassuring screening photograph does not rule out cataract, glaucoma or a later retinal problem. Tell an eye-care professional about new symptoms rather than relying on an earlier normal result. [1]
Do not wait for your next screening appointment if your vision changes. HSE gives this advice because symptoms need assessment outside the screening timetable. Sudden loss, a new curtain or a shower of floaters needs urgent advice. Explain when the change began and whether one or both eyes are affected so the appropriate service can assess urgency. [2]
You may need a visual-acuity check, dilated retinal examination and imaging selected for the suspected problem. AAO guidance combines these with your diabetes and eye history. Screening photographs can help, but do not settle every diagnosis. Bring previous reports and tell the team about earlier injections, laser or surgery, because those details affect interpretation and planning. [3]
OCT helps identify and measure macular swelling by showing retinal layers in cross-section. NICE recommends it when assessing for diabetic macular oedema. It can also help monitor response to treatment. The scan is interpreted with your sight and examination; a thicker retina does not by itself tell you which drug or procedure you need. [4]
Yes; long-term glucose management reduces retinal complications, as demonstrated in the DCCT. Work with your diabetes team on goals appropriate for you rather than changing medicines rapidly yourself. Eye disease can still need specific treatment, so improving blood results does not replace injections, laser or follow-up that have been recommended for your retinal findings. [9]
Yes; UKPDS showed benefits from blood-pressure control in people with diabetes and hypertension. NICE recommends appropriate hypertension care rather than blood-pressure medicines for everyone solely to prevent retinopathy. Share eye reports with your diabetes team, and follow the medical plan agreed for your general health. Do not stop or add treatment because of this guide alone. [10][4]
Yes; pre-existing diabetes in pregnancy needs a specific retinal assessment pathway. NICE and HSE describe closer attention because retinal changes can worsen. Tell your maternity, diabetes and eye-care teams if you are pregnant or planning pregnancy, especially if injections are being considered. Ordinary screening invitations should not be assumed to provide all the monitoring required. [13][2]
No; treatment depends on vision, the swelling pattern and other retinal findings. Protocol V supports careful observation for selected people with centre-involving swelling and good starting vision, with injections if vision worsens. That approach requires monitoring. It is not a reason to ignore swelling, miss reviews or defer assessment when sight has already deteriorated. [8]
They reduce a signal involved in abnormal vessel growth and leakage, helping to protect sight and reduce retinal swelling. Cambridge University Hospitals explains that the medicine is delivered directly into the eye. The response varies, and repeated treatment may be needed. Ask which retinal problem is being treated and how the team will judge whether it is working. [15]
No; the best choice depends on the eye and treatment circumstances. Protocol T found that starting vision influenced comparisons between medicines, while Cochrane describes limitations in longer-term comparisons. Discuss the proposed medicine, previous response and safety considerations. A trial average is not a personal forecast, and different brand names should not be assumed to guarantee different outcomes. [6][5]
They can improve vision in diabetic macular oedema, but the amount varies. Protocol T found improvement across its anti-VEGF treatment groups. Existing retinal damage, other eye disease and the starting level of sight can limit the result. Treatment may aim primarily to stabilise vision, so ask what benefit is realistic in your own eye. [6]
Laser may be recommended to reduce the risk from abnormal new vessels or to treat selected macular swelling. These are different uses. AAO guidance distinguishes panretinal treatment from macular treatment, with different visual trade-offs. Ask which problem the laser addresses, whether injections are also needed and what change the team expects to see afterwards. [3]
They are an option for selected eyes, but reliable follow-up matters. Protocol S supports considering visit attendance and practical treatment demands when choosing between injections and panretinal laser. Some eyes need a combination or a change of approach. Tell the team about transport or caring difficulties before agreeing to repeated visits rather than missing treatment later. [7]
Surgery may be considered for persistent bleeding or scar tissue pulling on the retina. NHS information describes operations that remove blood or scar tissue from the back of the eye. The surgeon assesses the structural problem and explains the likely benefit and restrictions. Surgery does not cure diabetes or make further retinal monitoring unnecessary. [12]
The surface is numbed with anaesthetic drops, although a brief scratch or pressure can still be uncomfortable. Guy’s and St Thomas’ describes this as usually not painful. Tell the team if you are worried or uncomfortable during the procedure. Severe pain afterwards, especially with worsening vision, needs urgent assessment rather than reassurance from the general description. [14]
Tell them about allergies, an infected or sticky eye, pregnancy and relevant recent illnesses or hospital care. Cambridge University Hospitals lists these as information that can affect the treatment discussion or timing. Bring your medicines and previous treatment details. The team should assess your circumstances; do not cancel or change a medicine yourself based on a general leaflet. [15]
It depends on severity and treatment. NICE gives examples of every 6–12 months for untreated moderate non-proliferative disease and 3–6 months for severe or very severe disease. Active treatment or new symptoms can need closer review. These are guideline ranges for defined situations, not an Irish screening schedule or a fixed clinic booking promise. [4]
Do not drive while your sight is blurred or otherwise unsafe after dilation or treatment. Guy’s and St Thomas’ advises arranging assistance or transport around eye injections. The time taken to recover varies, so a general interval does not establish fitness. Separate retinal field loss or other eye disease may also require a formal driving assessment. [14]
Severe or increasing pain, worsening redness, discharge, a curtain or a reduction in vision needs urgent contact with the treating team. Guy’s and St Thomas’ highlights these as possible signs of serious complications. If the service is unavailable, attend an emergency department. Do not assume worsening symptoms are ordinary healing or wait for the next planned injection. [14]
